| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/J.MOLBRAINRES.2004.09.017 |
| P8608 | Fatcat ID | release_5c23ui5sk5dxvkupw7b55y6vhe |
| P698 | PubMed publication ID | 15790530 |
| P50 | author | Vernice Jackson-Lewis | Q67189596 |
| P2093 | author name string | Richard Jay Smeyne | |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Parkinson's disease | Q11085 |
| P304 | page(s) | 57-66 | |
| P577 | publication date | 2005-03-01 | |
| P1433 | published in | Molecular Brain Research | Q6895939 |
| P1476 | title | The MPTP model of Parkinson's disease | |
| P478 | volume | 134 |
| Q92408380 | (E)-2-methoxy-4-(3-(4-methoxyphenyl) prop-1-en-1-yl) Phenol Ameliorates MPTP-Induced Dopaminergic Neurodegeneration by Inhibiting the STAT3 Pathway |
| Q53413619 | 90 years of monoamine oxidase: some progress and some confusion. |
| Q39266481 | A New Treatment Strategy for Parkinson's Disease Through the Gut-Brain Axis: The Glucagon-like Peptide-1 Receptor Pathway |
| Q51786227 | A New Treatment Strategy for Parkinson's Disease through the Gut-Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway. |
| Q39215656 | A disruption mechanism of the molecular clock in a MPTP mouse model of Parkinson's disease. |
| Q93105716 | A pilot study on assessment of locomotor behavior using a video tracking system in minipigs |
| Q36588388 | A-85380: a pharmacological probe for the preclinical and clinical investigation of the alphabeta neuronal nicotinic acetylcholine receptor. |
| Q97519933 | Abnormal Mitochondrial Quality Control in Neurodegenerative Diseases |
| Q38218083 | Advances in non-dopaminergic treatments for Parkinson's disease |
| Q27334826 | Allopregnanolone reinstates tyrosine hydroxylase immunoreactive neurons and motor performance in an MPTP-lesioned mouse model of Parkinson's disease |
| Q36056363 | Alteration in Nuclear Factor-KappaB Pathway and Functionality of Estrogen via Receptors Promote Neuroinflammation in Frontal Cortex after 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Treatment |
| Q35750220 | Altered dopamine metabolism and increased vulnerability to MPTP in mice with partial deficiency of mitochondrial complex I in dopamine neurons |
| Q50890705 | Animal care and use issues in movement disorder research. |
| Q50053102 | Behavioral, Biochemical and Molecular Characterization of a Parkinson's Disease Mouse Model Using the Neurotoxin 2'-CH3-MPTP: A Novel Approach |
| Q41108404 | Beneficial effects of L-arginine on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neuronal degeneration in substantia nigra of Balb/c mice |
| Q55362711 | Beta-carboline alkaloids and essential tremor: exploring the environmental determinants of one of the most prevalent neurological diseases. |
| Q43078902 | Biochemical alterations of the striatum in an MPTP-treated mouse model of Parkinson's disease |
| Q34032624 | Blood harmane (1-methyl-9H-pyrido[3,4-b]indole) concentrations in essential tremor: repeat observation in cases and controls in New York |
| Q41911647 | Ceftriaxone increases glutamate uptake and reduces striatal tyrosine hydroxylase loss in 6-OHDA Parkinson's model |
| Q36190765 | Cerebrospinal fluid-based kinetic biomarkers of axonal transport in monitoring neurodegeneration. |
| Q39359668 | Cholinergic and Dopaminergic Alterations in Nigrostriatal Neurons Are Involved in Environmental Enrichment Motor Protection in a Mouse Model of Parkinson's Disease |
| Q50280256 | Chronic and progressive Parkinson's disease MPTP model in adult and aged mice |
| Q36915459 | Chronic behavioral stress exaggerates motor deficit and neuroinflammation in the MPTP mouse model of Parkinson's disease |
| Q36773385 | Clavulanic acid inhibits MPP⁺-induced ROS generation and subsequent loss of dopaminergic cells |
| Q37148963 | Copper(II) binding to alpha-synuclein, the Parkinson's protein |
| Q42703530 | Daily rhythms of serotonin metabolism and the expression of clock genes in suprachiasmatic nucleus of rotenone-induced Parkinson's disease male Wistar rat model and effect of melatonin administration |
| Q64276142 | Deciduous DPSCs Ameliorate MPTP-Mediated Neurotoxicity, Sensorimotor Coordination and Olfactory Function in Parkinsonian Mice |
| Q91965965 | Delayed Dopamine Dysfunction and Motor Deficits in Female Parkinson Model Mice |
| Q40715534 | Differential Effects of Methyl-4-Phenylpyridinium Ion, Rotenone, and Paraquat on Differentiated SH-SY5Y Cells |
| Q37097033 | Differential effects of the dopamine neurotoxin MPTP in animals with a partial deletion of the GDNF receptor, GFR alpha1, gene |
| Q37076753 | Distinct mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine resistance revealed by transcriptome mapping in mouse striatum |
| Q59808993 | Effect of NAC treatment and physical activity on neuroinflammation in subchronic Parkinsonism; is physical activity essential? |
| Q96135942 | Effect of treadmill exercise on catalepsy and the expression of the BDNF gene in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine -induced Parkinson in male NMRI mice |
| Q24656692 | Elevated blood harmane (1-methyl-9H-pyrido[3,4-b]indole) concentrations in essential tremor |
| Q37200585 | Elevated brain harmane (1-methyl-9H-pyrido[3,4-b]indole) in essential tremor cases vs. controls |
| Q48314703 | Environmental enrichment does not reduce the rewarding and neurotoxic effects of methamphetamine. |
| Q37196824 | Environmental epidemiology of essential tremor |
| Q38715276 | Essential Dietary Bioactive Lipids in Neuroinflammatory Diseases |
| Q30478476 | Estrogen actions in the brain and the basis for differential action in men and women: a case for sex-specific medicines |
| Q62272734 | Evaluation of Nigrostriatal Neurodegeneration and Neuroinflammation Following Repeated Intranasal 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Administration in Mice, an Experimental Model of Parkinson’s Disease |
| Q37812392 | Exercise alleviates Parkinsonism: clinical and laboratory evidence |
| Q33907587 | Exercise protects against MPTP-induced neurotoxicity in mice. |
| Q34706597 | Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration |
| Q35616756 | GSTpi expression mediates dopaminergic neuron sensitivity in experimental parkinsonism |
| Q34145821 | Genetic dissection of strain dependent paraquat-induced neurodegeneration in the substantia nigra pars compacta |
| Q37298364 | Geraniol ameliorates the motor behavior and neurotrophic factors inadequacy in MPTP-induced mice model of Parkinson's disease |
| Q37466357 | Glial cell line-derived neurotrophic factor partially ameliorates motor symptoms without slowing neurodegeneration in mice with respiratory chain-deficient dopamine neurons. |
| Q49698299 | Glut9-mediated Urate Uptake Is Responsible for Its Protective Effects on Dopaminergic Neurons in Parkinson's Disease Models |
| Q35915111 | HIF1α is necessary for exercise-induced neuroprotection while HIF2α is needed for dopaminergic neuron survival in the substantia nigra pars compacta |
| Q29619113 | High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease |
| Q42030555 | Human pluripotent stem cell derived midbrain PITX3(eGFP/w) neurons: a versatile tool for pharmacological screening and neurodegenerative modeling |
| Q64990227 | Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels: An Emerging Role in Neurodegenerative Diseases. |
| Q42565249 | ICP10PK inhibits calpain-dependent release of apoptosis-inducing factor and programmed cell death in response to the toxin MPP+. |
| Q30503280 | Impaired mitochondrial transport and Parkin-independent degeneration of respiratory chain-deficient dopamine neurons in vivo |
| Q34682391 | Impaired nigrostriatal function precedes behavioral deficits in a genetic mitochondrial model of Parkinson's disease |
| Q50025519 | In vivo GluCEST MRI: Reproducibility, background contribution and source of glutamate changes in the MPTP model of Parkinson's disease |
| Q37524567 | Independent influences of sex steroids of systemic and central origin in a rat model of Parkinson's disease: A contribution to sex-specific neuroprotection by estrogens. |
| Q46247320 | Inhibitory effects of curcumin and cyclocurcumin in 1-methyl-4-phenylpyridinium (MPP+) induced neurotoxicity in differentiated PC12 cells |
| Q53575010 | Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons. |
| Q85125086 | Iron mediates neuritic tree collapse in mesencephalic neurons treated with 1-methyl-4-phenylpyridinium (MPP+) |
| Q55419599 | JNK-mediated microglial DICER degradation potentiates inflammatory responses to induce dopaminergic neuron loss. |
| Q42941876 | Licofelone attenuates MPTP-induced neuronal toxicity: behavioral, biochemical and cellular evidence |
| Q36019710 | Long-lasting transcriptional refractoriness triggered by a single exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine |
| Q46765629 | Lutein protects dopaminergic neurons against MPTP-induced apoptotic death and motor dysfunction by ameliorating mitochondrial disruption and oxidative stress |
| Q39989829 | MPP(+) -dependent inhibition of Ih reduces spontaneous activity and enhances EPSP summation in nigral dopamine neurons |
| Q39959282 | MPP(+)-induced cytotoxicity in neuroblastoma cells: Antagonism and reversal by guanosine |
| Q64913888 | MPTP-driven NLRP3 inflammasome activation in microglia plays a central role in dopaminergic neurodegeneration. |
| Q35972056 | Male/Female differences in neuroprotection and neuromodulation of brain dopamine |
| Q33844949 | Metabolic Investigations of the Molecular Mechanisms Associated with Parkinson's Disease |
| Q38815779 | Microglial phenotypes in Parkinson's disease and animal models of the disease |
| Q26784216 | Mitochondria: A Therapeutic Target for Parkinson's Disease? |
| Q30444758 | Mitochondrial dysfunction and oxidative stress in Parkinson's disease. |
| Q33605431 | Mitochondrial dysfunction in mouse models of Parkinson's disease revealed by transcriptomics and proteomics |
| Q37796012 | Modeling neuroinflammatory pathogenesis of Parkinson’s disease |
| Q46723175 | Neurochemical evidence for agmatine modulation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity |
| Q27027973 | Neuroimmunological processes in Parkinson's disease and their relation to α-synuclein: microglia as the referee between neuronal processes and peripheral immunity |
| Q34672936 | Neuroprotective Effects of Alpha-Mangostin on MPP(+)-Induced Apoptotic Cell Death in Neuroblastoma SH-SY5Y Cells |
| Q46236559 | Neurotoxicity of pesticides: its relationship with neurodegenerative diseases |
| Q39229450 | Non-human primate models of PD to test novel therapies |
| Q42375123 | Opposed Effects of Dityrosine Formation in Soluble and Aggregated α-Synuclein on Fibril Growth |
| Q84152956 | Oral administration of coenzyme Q₁₀ reduces MPTP-induced loss of dopaminergic nerve terminals in the striatum in mice |
| Q34203215 | Oxidative toxicity in neurodegenerative diseases: role of mitochondrial dysfunction and therapeutic strategies |
| Q38701632 | P7C3 inhibits GSK3β activation to protect dopaminergic neurons against neurotoxin-induced cell death in vitro and in vivo |
| Q37071201 | Parkinson's disease and enhanced inflammatory response. |
| Q24311461 | Parkinsonian neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and alpha-synuclein mutations promote Tau protein phosphorylation at Ser262 and destabilize microtubule cytoskeleton in vitro |
| Q36275187 | Pharmacological inhibition of neuronal NADPH oxidase protects against 1-methyl-4-phenylpyridinium (MPP+)-induced oxidative stress and apoptosis in mesencephalic dopaminergic neuronal cells |
| Q64056321 | Potential Pharmacokinetic Drug⁻Drug Interaction Between Harmine, a Cholinesterase Inhibitor, and Memantine, a Non-Competitive -Methyl-d-Aspartate Receptor Antagonist |
| Q40462891 | Pretreatment of caffeine leads to partial neuroprotection in MPTP model of Parkinson's disease. |
| Q58486541 | Prevention of progression in Parkinson's disease |
| Q49059583 | Profiling changes in gait dynamics resulting from progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigrostriatal lesioning |
| Q45969420 | Progressive dopaminergic degeneration in the chronic MPTPp mouse model of Parkinson's disease. |
| Q35611727 | Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons |
| Q51839227 | Reduced calcium/calmodulin-dependent protein kinase II activity in the hippocampus is associated with impaired cognitive function in MPTP-treated mice. |
| Q28740694 | Regulation of bat echolocation pulse acoustics by striatal dopamine |
| Q38862845 | Regulation of striatal astrocytic receptor for advanced glycation end-products variants in an early stage of experimental Parkinson's disease |
| Q34279991 | Relationship between blood harmane and harmine concentrations in familial essential tremor, sporadic essential tremor and controls |
| Q42501050 | Respiratory chain inhibition: one more feature to propose MPTP intoxication as a Leigh syndrome model. |
| Q36156158 | Response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) differs in mouse strains and reveals a divergence in JNK signaling and COX-2 induction prior to loss of neurons in the substantia nigra pars compacta |
| Q35541410 | Salidroside induces rat mesenchymal stem cells to differentiate into dopaminergic neurons |
| Q37725727 | Silymarin improved 6-OHDA-induced motor impairment in hemi-parkisonian rats: behavioral and molecular study |
| Q50235339 | Succinobucol, a Non-Statin Hypocholesterolemic Drug, Prevents Premotor Symptoms and Nigrostriatal Neurodegeneration in an Experimental Model of Parkinson's Disease |
| Q36367293 | Supramolecular Inhibition of Neurodegeneration by a Synthetic Receptor |
| Q53343059 | TGF-β1 Neuroprotection via Inhibition of Microglial Activation in a Rat Model of Parkinson's Disease. |
| Q39392775 | Targeting Microglial Activation States as a Therapeutic Avenue in Parkinson's Disease |
| Q48282700 | Tauroursodeoxycholic Acid Protects Against Mitochondrial Dysfunction and Cell Death via Mitophagy in Human Neuroblastoma Cells |
| Q92406209 | The Ameliorative Effects of the Ethyl Acetate Extract of Salicornia europaea L. and Its Bioactive Candidate, Irilin B, on LPS-Induced Microglial Inflammation and MPTP-Intoxicated PD-Like Mouse Model |
| Q30376382 | The Solution Structure and Dynamics of Full-length Human Cerebral Dopamine Neurotrophic Factor and Its Neuroprotective Role against α-Synuclein Oligomers. |
| Q38202314 | The centrality of mitochondria in the pathogenesis and treatment of Parkinson's disease |
| Q64811522 | The role of posttranslational modifications of α-synuclein and LRRK2 in Parkinson's disease: Potential contributions of environmental factors |
| Q36052708 | The use of MALDI-MSI in the investigation of psychiatric and neurodegenerative disorders: A review. |
| Q39609930 | Type-1 interferons contribute to the neuroinflammatory response and disease progression of the MPTP mouse model of Parkinson's disease. |
| Q48355383 | URB597 and the Cannabinoid WIN55,212-2 Reduce Behavioral and Neurochemical Deficits Induced by MPTP in Mice: Possible Role of Redox Modulation and NMDA Receptors |
| Q40994447 | Use of intraoperative local field potential spectral analysis to differentiate basal ganglia structures in Parkinson's disease patients |
| Q34596492 | Viral parkinsonism. |
| Q49349652 | Whole-Transcriptome Analysis of Mouse Models with MPTP-Induced Early Stages of Parkinson's Disease Reveals Stage-Specific Response of Transcriptome and a Possible Role of Myelin-Linked Genes in Neurodegeneration |
| Q30493208 | Zebrafish: An in vivo model for the study of neurological diseases |
| Q46683287 | Zingerone activates VMAT2 during MPP(+) -induced Cell Death |
Search more.